卡维地洛与美托洛尔治疗慢性心力衰竭疗效比较

The comparison observation of carvedilol and metoprolol in treatment patients with chronic heart failure and its effect on TNF-α and IL-6

目的对比观察卡维地洛于美托洛尔治疗慢性心力衰竭（CHF）的疗效及对肿瘤坏死因子（TNF-α）和白细胞介素-6（IL-6）水平影响。方法94例CHF患者随机分为卡维地洛组和美托洛尔组，每组47例，比较观察两组的临床疗效及对TNF—α和IL-6水平影响。结果卡维地洛组的总有效率明显高于美托洛尔组，两组比较差异有统计学意义（P〈0．05）。两组治疗后TNF-α和IL-6水平都较治疗前明显下降，差异有统计学意义（P〈0．05）。卡维地洛组治疗后TNF-α和IL-6水平明显低于卡维地洛组，差异有统计学意义（P〈0．05）。结论卡维地洛治疗CHF的临床疗效明显高于美托洛尔，并且卡维地洛较美托洛尔更明显降低血浆TNF—α和IL-6水平，是目前治疗CHF的一种首选药物。

Objective To observe the effect of carvedilol and metoprolol in patients with chronic heart failure （CHF） and its effect on TNF-α and IL-6. Methods 94 cases of CHF were randomly classified into carvedilol group with 47 cases and metoprolol group with 47 cases, which were treated with metoprolol and metoprolol, respectively. The clinical effects and the lovels of TNF-α and IL-6 were compared. Results The clinical effective rate in carvedilol group was significantly higher than that in metoprolol group （ P 〈 0.05 ）. After treatment, the levels of TNF-α and IL-6 were significantly decreased in both groups （ P 〈 0.05 ）. Moreover, the levels of TNF-α and IL-6 in earvedilol group were significandy lower than those in metoprolol group after treatment （ P 〈 0. 05 ）. Conclusion Carvedilol in improving clinical effective rate and decreasing the levels of TNF-α and IL-6 was better than metoprolol, which played an important role in treatment of CHF.